Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study.

C Busca-ArenzanaD Ortega-GonzálezM Díaz-AlmirónM L MontesLuz Martin-CarboneroR MicanR MontejanoLuis Ramos-RupertoEulalia ValenciaAna Delgado-HierroJose Ignacio Bernardino

Published in: HIV medicine (2024)

In our real-life cohort, the effect of switching TDF-/TAF-sparing regimens to triple therapy with B/F/TAF improved total cholesterol, triglycerides, and serum markers of HS at 6 months and was neutral for the remaining metabolic parameters at 12 months.

Keyphrases

antiretroviral therapy
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
hiv infected patients
hiv testing
men who have sex with men
south africa
low density lipoprotein
cell therapy
mesenchymal stem cells